Observational study of iris tumors using imaging techniques
Observational Study of Iris Tumors
Oregon Health and Science University · NCT03809585
This study is trying to learn more about iris tumors by using special imaging techniques to compare them with healthy eyes in people who have these tumors and those who don’t.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Oregon Health and Science University (other) |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT03809585 on ClinicalTrials.gov |
What this trial studies
This observational study utilizes Optical Coherence Tomography (OCT) angiography to characterize melanotic and amelanotic iris tumors by comparing imaging data from affected eyes to healthy controls. The study aims to enhance understanding of iris tumors and their vascular characteristics. Participants include individuals diagnosed with iris tumors as well as healthy individuals without any iris lesions. The study will not involve any treatments or interventions, focusing solely on data collection and analysis.
Who should consider this trial
Good fit: Ideal candidates include individuals with diagnosed melanotic or amelanotic iris tumors and healthy individuals without iris defects.
Not a fit: Patients with concurrent retinal diseases, glaucoma, or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve diagnostic accuracy and management strategies for patients with iris tumors.
How similar studies have performed: While there have been studies using OCT in other ocular conditions, this specific approach to iris tumors is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria for tumor group: * Eyes with diagnosis of melanotic or amelanotic iris tumors Inclusion Criteria for healthy control group: * Eyes without iris defects or lesions Exclusion Criteria (both groups): * Inability to give informed consent * Inability to maintain stable fixation for OCT imaging * Inability to commit to required study visits * Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation * Mature cataracts if found to limit visual potential to worse than 20/40
Where this trial is running
Portland, Oregon
- Oregon Health & Science University — Portland, Oregon, United States (RECRUITING)
Study contacts
- Principal investigator: David Huang, MD, PhD — Oregon Health and Science University
- Study coordinator: Denzil Romfh, OD
- Email: romfhd@ohsu.edu
- Phone: 503-494-4351
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Iris Tumor, Iris, Tumor, Melanoma, Optical Coherence Tomography, Angiography